{"brief_title": "Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)", "brief_summary": "The purpose of the study is to determine if an investigational vaccine with a single component develops an immune response that is similar to the equivalent investigational vaccine with four components to reduce cervical disease.", "condition": ["Cervical Cancer", "Genital Warts"], "intervention_type": ["Biological"], "intervention_name": ["V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years"], "criteria": "Inclusion Criteria: - Female with an intact uterus with lifetime history of 0-4 sexual partners Exclusion Criteria: - Prior Human Papillomavirus Vaccine (HPV) vaccination; - Prior abnormal paps; - Prior history of genital warts", "gender": "Female", "minimum_age": "16 Years", "maximum_age": "23 Years", "healthy_volunteers": "Accepts Healthy Volunteers", "mesh_term": ["Uterine Cervical Neoplasms", "Condylomata Acuminata", "Vaccines"], "id": "NCT00092482"}